Cure8 research brief
If validated, a genetic marker (IL12B rs6887695) might help predict which patients are more likely to benefit from ustekinumab, potentially informing personalized treatment choices in IBD.
Clinicians treating IBD, researchers in IBD pharmacogenetics and biomarkers, patients considering or on ustekinumab, and guideline developers interested in precision medicine.
This observational cohort of 98 IBD patients treated with ustekinumab reports that 74.5% achieved steroid-free remission at 12 months and 16.3% discontinued treatment during follow-up.
The authors tested four SNPs and found that carriers of the IL12B rs6887695 variant had higher odds of steroid-free remission and a lower hazard of treatment discontinuation compared with wild-type patients.
The finding is exploratory and hypothesis-generating: the authors state it needs validation in larger, independent cohorts before it could guide clinical decisions. Keep the takeaway cautious: this is real-world observational data with a modest sample size and focused genetic testing; it suggests a potential biomarker but does not establish clinical utility.
This is an observational cohort (n=98) and the authors describe the genetic association as exploratory; external validation in larger, independent cohorts is needed before using this marker in routine care.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...
People with moderate-to-severe Crohn's disease or ulcerative colitis and their clinicians may want to know how long patients stay on guselkumab in real-world care, since persistence reflects tolerability, benefit, and...
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
